Ultra-early Identification of Fetal Chromosomal Characteristics From Extravillous-trophoblast Cells

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Jul 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new, non-invasive method to check for chromosomal abnormalities in a developing fetus early in pregnancy. The goal is to identify potential genetic issues from a very early stage, which could help parents make informed decisions about their pregnancy. This method uses a sample from a specific type of cells found in the placenta, making it safer and less invasive than traditional testing.

To participate in this trial, women must be pregnant with one baby and between 7 to 16 weeks along in their pregnancy. They should be at least 18 years old and willing to give their consent to join the study. While the trial is currently recruiting participants, it is important to note that women who are under legal protection or unable to provide consent cannot take part. If eligible, participants can expect to undergo this new testing method and contribute to important research that may improve prenatal care for future pregnancies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant woman
• • Singleton pregnancy
• • Pregnancy between 7 and 16 weeks of amenorrhea (WA)
• • Woman ≥ 18 years
• • Woman who has signed an informed consent
• • Woman affiliated to social security or equivalent scheme
• Exclusions Criteria:
• • Person under guardianship or curatorship
• • Person placed under legal protection
• • Person unable to provide the participant with informed consent.